Phagenesis Launches First Treatment for Acute Dysphagia

26-Oct-2012 - United Kingdom

Phagenesis launches the world's first approved treatment for acute dysphagia following stroke. The Phagenyx™ system delivers calibrated electrical stimulus to the throat (oropharynx) for 10 minutes a day for three consecutive days to patients who suffer from dysphagia – the inability to swallow safely - a debilitating condition that affects about half of all stroke patients. Randomised controlled clinical trials show that this protocol leads to statistically significant improvements in patients' swallowing function.

Daniel Green, CEO of Phagenesis, said: “Within the last few months, the team has worked tirelessly to get the product to where it is today. By bringing this product to market, we are providing physicians with the tools they need to treat dysphagia and alleviate the suffering of many stroke patients.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances